Leukocyte immunoglobulin-like receptor: Difference between revisions
No edit summary |
Michal Harel (talk | contribs) No edit summary |
||
(8 intermediate revisions by 2 users not shown) | |||
Line 1: | Line 1: | ||
<StructureSection load='' size='350' side='right' caption='Structure of human leukocyte immunoglobulin-like receptor ligand-binding domain (salmon) complex with class I MHC (aqua), β-2 microglobulin (green) and POL polyprotein peptide (pink) (PDB entry [[1p7q]])' scene='55/552188/Cv/3'> | <StructureSection load='' size='350' side='right' caption='Structure of human leukocyte immunoglobulin-like receptor ligand-binding domain (salmon) complex with class I MHC (aqua), β-2 microglobulin (green) and POL polyprotein peptide (pink) (PDB entry [[1p7q]])' scene='55/552188/Cv/3'> | ||
'''Leukocyte immunoglobulin-like receptors''' (LIR) or '''CD85''' have extracellular immunoglobulin domains. LIR modulates a variety of immune cells. LIR interacts with class I MHC molecules<ref>PMID:19548123</ref>. <scene name='55/552188/Cv/ | '''Leukocyte immunoglobulin-like receptors''' (LIR) or '''CD85''' have extracellular immunoglobulin domains. LIR modulates a variety of immune cells. LIR interacts with class I MHC molecules<ref>PMID:19548123</ref>. <scene name='55/552188/Cv/6'>Leukocyte immunoglobulin-like receptor complex with class I MHC, β-2 microglobulin and POL polyprotein peptide</scene> (PDB entry [[1p7q]]). <scene name='55/552188/Cv/7'>Interactions between LIR and class I MHC, β-2 microglobulin</scene>. | ||
*'''LILRA2''' is an activating receptor that inhibits dendritic cell differentiation. | |||
*'''LILRA5''' has a role in triggering innate immune responses. | |||
*'''LILRB1''' interacts with classical and non-classical human leukocyte antigen (HLA) class I molecules<ref>PMID:37781391</ref>. | |||
*'''LILRB3''' is a target for treatment against acute myeloid leukaemia<ref>PMID:38098451</ref>. | |||
*'''LILRB4''' suppresses immunity in solid tumors<ref>PMID:33974041</ref>. | |||
See also: | |||
*[[Immune receptors]] | |||
*[[Receptor]] | |||
</StructureSection> | </StructureSection> | ||
Line 9: | Line 19: | ||
{{#tree:id=OrganizedByTopic|openlevels=0| | {{#tree:id=OrganizedByTopic|openlevels=0| | ||
* | *LILR; ligand-binding domain D1D2 27-221; ligand-binding domain D3D4 222-417 | ||
*LILRA2 subfamily A member 2 | |||
**[[2otp]] – hLILRA2 ligand-binding domain D1D2 - human<br /> | |||
*LILRA3 subfamily A member 3 | |||
**[[3q2c]] – hLILRA3 N-terminal domain <br /> | |||
*LILRA5 subfamily A member 5 | |||
**[[2d3v]] – hLILRA5 extracerllular domain <br /> | |||
**[[1vdg]] – hLILRA5 ligand-binding domain D1D2 (mutant) <br /> | |||
* | *LILRB1 subfamily B member 1 | ||
* | **[[1g0x]] – hLILRB1 ligand-binding domain D1D2<br /> | ||
**[[1ugn]] – hLILRB1 ligand-binding domain D1D2 (mutant) <br /> | |||
**[[4ll9]] – hLILRB1 ligand-binding domain D3D4 <br /> | |||
**[[7kfk]] – hLILRB1 ligand-binding domain D3D4 + Rifin<br /> | |||
**[[6zdx]] – hLILRB1 ectodomain + Rifin<br /> | |||
**[[1p7q]] – hLILRB1 ligand-binding domain D1D2 + class I MHC + β-2 microglobulin + POL polyprotein peptide<br /> | |||
**[[4no0]], [[5knm]], [[6aee]], [[6ewa]], [[6ewc]], [[6ewo]], [[6k60]] – hLILRB1 ligand-binding domain D1D2 + class I MHC + β-2 microglobulin + peptide<br /> | |||
**[[3d2u]] – hLILRB1 ligand-binding domain D1D2 + herpesvirus UL18 + β-2 microglobulin + actin peptide<br /> | |||
* | *LILRB2 subfamily B member 2 | ||
* | **[[4lla]] – hLILRB2 ligand-binding domain D3D4 <br /> | ||
**[[6aed]] – hLILRB2 ligand-binding domain D1D2D3D4 (mutant)<br /> | |||
**[[2gw5]] – hLILRB2 ligand-binding domain D1D2 <br /> | |||
**[[6bcs]] – hLILRB2 ligand-binding domain D1D2 + benzamidine<br /> | |||
**[[2dyp]] – hLILRB2 ligand-binding domain D1D2 + class I MHC + β-2 microglobulin + H2A peptide<br /> | |||
* | *LILRB3 subfamily B member 3 | ||
* | **[[6grq]], [[6grs]], [[6grt]] – mLILRB3 extracellular domain 25-619 <br /> | ||
* | *LILRB4 subfamily B member 4 | ||
* | **[[3p2t]] – hLILRB4 ligand-binding domain D1D2 <br /> | ||
**[[6k7o]] – hLILRB4 N-terminal domain + antibody <br /> | |||
}} | }} | ||
== References == | == References == | ||
<references/> | <references/> | ||
[[Category:Topic Page]] | [[Category:Topic Page]] |